Showing 5561-5570 of 7901 results for "".
- Aesyntix Partners With Sentéhttps://practicaldermatology.com/news/20130125-aesyntix_partners_with_sent/2459626/Aesyntix Physician Network (APN), a group purchasing organization and subsidiary of Aesyntix Health, Inc., entered into an agreement with Senté, Inc., a privately held cosmeceutical company that develops differentiated medical skincare pro
- Provectus Launches Free Investor Relations Apphttps://practicaldermatology.com/news/20130124-provectus_launches_free_investor_relations_app/2459627/Provectus Pharmaceuticals, Inc. launched a free mobile shareholder investor relations application. The app offers immediate portable access to the company's latest news, financial information, presentations, and factsheet. The "Provectus IR" app is a
- Study: Most Skin-Cancer Apps Unreliablehttps://practicaldermatology.com/news/20130123-study_most_skin-cancer_apps_unreliable/2459630/The University of Pittsburgh studied four smartphone apps that evaluate melanoma by analyzing images submitted by the users. One app works by having a board-certified dermatologist look at the photos, while the other three apps analyze the images by computer algorithm. The best-performing of the com
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe
- BOTOX Receives FDA Approval for Overactive Bladderhttps://practicaldermatology.com/news/20130121-botox_receives_fda_approval_for_overactive_bladder/2459633/The US FDA just approved BOTOX (onabotulinumtoxinA) from Allergan, Inc. for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults who have had an inadequate response to or are intol
- Viscot Medical Introduces the AllSkin Plus+https://practicaldermatology.com/news/20130110-viscot_medical_introduces_the_allskin_plus/2459644/Viscot Medical released the AllSkin Plus+, a prep resistant ink marker that offers maximum visibility and prep resistance on all skin tones. According to the company, the VIXL brilliant blue ink provides enhanced visibility even after prepping with
- Apremilast Meets Endpoints in Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/20130108-apremilast_meets_endpoints_in_phase_3_psoriasis_trials/2459645/Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving apremilast 30 mg BID monotherapy in both the ESTEEM
- DermOne Acquires Atlantic Dermatologyhttps://practicaldermatology.com/news/20130107-dermone_acquires_atlantic_dermatology/2459647/DermOne closed on the acquisition of Atlantic Dermatology of Wilmington, NC on December 31, 2012. Atlantic Dermatology specializes in cosmetic, laser, medical, and surgical dermatolo
- North American Facial Injectable Market to Hit $1.7 Billion by 2017https://practicaldermatology.com/news/20121228-north_american_facial_injectable_market_to_hit_17_billion_by_2017/2459652/According to Millennium Research Group, the North American facial injectables market, comprising botulinum toxin and dermal fillers sold in the US and Canada, will continue to show strong growth for the next five years, reaching a total value of more
- Allergan Acquires SkinMedicahttps://practicaldermatology.com/news/20121221-allergan_acquires_skinmedica/2459654/Allergan, Inc. completed the acquisition of SkinMedica, Inc. Under the terms of the agreement, which was first announced on November 16, 2012, Allergan paid approximately $350 million (subject to certain adjustments) for the business, which inclu